Subcutaneously implanted central venous access devices in cancer patients: A prospective analysis Academic Article Article uri icon

Overview

MeSH Major

  • Melanoma

abstract

  • Subcutaneous intravenous access ports in cancer patients are safe and well tolerated. Long term device duration is primarily influenced by patient survival. In this study, 90% of patients alive at 1 year and 70% of patients alive at 4 years had a functional port.

publication date

  • April 15, 1997

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/(SICI)1097-0142(19970415)79:8<1635::AID-CNCR30>3.0.CO;2-X

PubMed ID

  • 9118051

Additional Document Info

start page

  • 1635

end page

  • 40

volume

  • 79

number

  • 8